Humanigen jumps on positive results for key drug

Humanigen

02/12/2021 14:22

** Biopharmaceutical co Humanigen's shares  HGEN.O  up ~9%
at $6.07 premarket
    ** The Lancet Respiratory Medicine published peer-reviewed
paper and independent expert commentary on positive results for 
HGEN's key drug Lenzilumab  urn:newsml:reuters.com:*:nBw1c6XKKa
    ** The drug significantly improved survival without invasive
mechanical ventilation in hospitalised patients with COVID-19,
according to the paper
    ** HGEN has fallen by ~63.12% since Sept after U.S. FDA
declined emergency use approval for its COVID-19 drug
 urn:newsml:reuters.com:*:nL4N2QB2CI
    ** 5 of 9 brokerages rate the stock "buy" or higher, 3
"hold" and 1 "sell"; their median PT is $18 - Refinitiv data
    ** Up to last close, stock had fallen 68.17% this year

 (Reporting by Bansari Mayur Kamdar in Bengaluru)
 ((BansariMayur.Kamdar@thomsonreuters.com;))